Full-Time

Associate Director

Quality Assurance, Validation

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$192k - $199kAnnually

Expert

San Carlos, CA, USA

This is a hybrid position, requiring some in-office days.

Category
QA & Testing
Quality Assurance
Required Skills
Risk Management

You match the following Vaxcyte's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BS or BA with 10+ years relevant industry experience.
  • Demonstrate in-depth knowledge of GMPs, FDA and EU requirements and ICH guidelines.
  • Must have a strong understanding of quality assurance principles and validation methodologies.
  • Possess technical knowledge of manufacturing processes and equipment.
  • Excellent analytical and problem-solving skills to interpret data and identify root causes.
  • Strong project management skills with the ability to manage multiple projects simultaneously.
  • Knowledge and experience in Risk Management principles.
  • Strong Management and process improvement skills.
  • Demonstrate a high level of independent quality judgment.
  • Demonstrate excellent verbal, written, and interpersonal communication skills.
  • Demonstrate experience leading and contributing through influence and working in cross functional teams.
  • Strong sense of ownership in areas of responsibility.
  • Ability to travel up to 30% domestically and internationally.
Responsibilities
  • Provide guidance and oversight of validation activities across all manufacturing and production processes within the organization.
  • Drive validation/qualification strategy and ensure continuous improvement of validation practices across the organization.
  • Ensure adherence to regulatory requirements by reviewing validation documentation and maintain compliance with relevant standards.
  • Participate in the design of validation/qualification activities.
  • Maintain Validation Master Plans, Project Validation/Qualification plans, risk assessments, protocols, and reports to GMP standards.
  • Identify areas for improvement within validation activities, propose changes to optimize procedures and enhance efficiency.
  • Identify potential risk associated with processes and product and collaborate with subject matter experts to implement mitigation strategies to minimize quality issues.
  • Work closely with manufacturing, regulatory, and quality operations to address quality concerns.
  • Stay updates on industry trends and regulatory changes to ensure compliance in validation processes.
  • Participate in root cause analysis for validation deviations, developing corrective and preventative actions.
  • Establish and revise quality assurance procedures and policies.
  • Promote a quality mindset and quality excellence approach to all activities.
Desired Qualifications
  • Vaccine experience desired.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

1%

1 year growth

2%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options